A Phase 1 interventional study of VX-548 in Pain, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 2 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-20.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing suzetrigine in Pain — 4 open to participants now, 4 under way, 2 of them phase 3. suzetrigine · Pain.
Among the 21 studies testing suzetrigine in Pain, this one is the 15th largest by enrollment, is one of 4 that started in 2022, is one of 15 in phase 1, and was the 3rd registered.
10,069 studies on the registry are indexed under Pain; 1,651 are open to participants now.
Browse Pain studies →4 of the 21 studies testing suzetrigine in Pain are open now, in 1 country. Recruiting first, the newest first:
Hospital for Special Surgery, New York · Sites in United States
Ages 18–80 · Healthy volunteers
Hospital for Special Surgery, New York · Sites in United States
Ages 18–80 · Healthy volunteers
Stanford University · Sites in United States
Ages 18+
Jacob Lensing · Sites in United States
Ages 18–45
By country, each count listing its studies:
suzetrigine: first FDA approval 2025 (JOURNAVX). What it is approved for, and how studies give it, is on its page →
Of the 928 Pain studies recruiting now, 383 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 222 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2022; this study’s year is marked. 4 started in 2022.
This study's enrollment of 36 is below the median of 66 across 8,502 interventional studies indexed under Pain.
Median enrollment 50 across the 21 interventional studies. Of the 17 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 21 have an industry lead sponsor. The 6 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
26 studies in Pain by Vertex Pharmaceuticals Incorporated: none open now, none under way, none of them phase 3. Of 26 finished, 1 (4%) have results posted.
Among the 26 studies in Pain by Vertex Pharmaceuticals Incorporated, this one is the 16th largest by enrollment, is one of 7 that started in 2022, is one of 24 in phase 1, and was the 5th registered.
Vertex Pharmaceuticals Incorporated’s Pain studies by the year they started, since 2022.
2 of the studies testing suzetrigine in Pain that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07226700Phase 3Hospital for Special Surgery, New YorkSuzetrigine in Total Hip Arthroplasty | 2027-11-01 |
| NCT07821931Stanford UniversitySuzetrigine in Tonsillectomy for Opioid-sparing Pain Management | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 21 studies testing suzetrigine in Pain, from their registry updates:
Among Vertex Pharmaceuticals Incorporated’s 26 in Pain:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the pharmacokinetics and safety of multiple doses of VX-584 in participants with mild or moderate hepatic impairment as compared to matched healthy controls.
This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4) (A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).
Key Inclusion Criteria:
Cohorts 1 and 3: Participants with Mild or Moderate Hepatic Impairment
Cohorts 2 and 4: Matched Healthy Participants
Key Exclusion Criteria:
Cohorts 1 and 3: Participants with Mild or Moderate Hepatic Impairment
Cohorts 2 and 4: Matched Healthy Participants
Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive multiple doses of VX-548 every 12 hours (q12h) from Day 1 through Day 14.
Drug: VX-548
Healthy participants matched to cohort 1 will receive multiple doses of VX-548 q12h from Day 1 through Day 14.
Drug: VX-548
Participants will receive multiple doses of VX-548 q12h from Day 1 through Day 14.
Drug: VX-548
Healthy participants matched to cohort 3 will receive multiple doses of VX-548 q12h from Day 1 through Day 14.
Drug: VX-548
Tablets for oral administration.
Also known as: Suzetrigine
Maximum Observed Plasma Concentration (Cmax) of VX-548
Time frame: Day 1 to Day 31
Area Under the Plasma Concentration Versus Time Curve During a Dosing Interval (AUCtau) of VX-548
Time frame: Day 1 to Day 31
Time Taken for VX-548 to Reach Maximum Concentration (tmax)
Time frame: Day 1 to Day 31
Time Required for Plasma Concentration of VX-548 to Reduce to Half (t1/2)
Time frame: Day 1 to Day 31
Apparent Volume of Distribution of VX-548 (Vz/F)
Time frame: Day 1 to Day 31
Apparent Clearance of VX-548 (CL/F)
Time frame: Day 1 to Day 31
Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to the Last Measured Concentration (AUC0-last) of VX-548
Time frame: Day 1 to Day 31
Maximum Observed Plasma Concentration (Cmax) of VX-548 Metabolite
Time frame: Day 1 to Day 31
Area Under the Plasma Concentration Versus Time Curve During a Dosing Interval (AUCtau) of VX-548 Metabolite
Time frame: Day 1 to Day 31
Time Taken for VX-548 metabolite to Reach Maximum Concentration (tmax)
Time frame: Day 1 to Day 31
Time Required for Plasma Concentration of VX-548 Metabolite to Reduce to Half (t1/2)
Time frame: Day 1 to Day 31
Apparent Volume of Distribution of VX-548 Metabolite (Vz/F)
Time frame: Day 1 to Day 31
Apparent Clearance of VX-548 Metabolite (CL/F)
Time frame: Day 1 to Day 31
Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to the Last Measured Concentration (AUC0-last) of VX-548 Metabolite
Time frame: Day 1 to Day 31
Fraction Unbound (fu) for VX-548 and its Metabolite in Plasma
Time frame: Day 14: Up to 24 hours Post-dose
Unbound Area Under the Concentration Versus Time Curve of VX-548 and its Metabolite
Time frame: Day 14: Up to 24 hours Post-dose
Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: From Day 1 up to Day 42
Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing
No publications or documents are linked to this record.
Ran from Oct 2022 to primary completion in Jul 2023, 9 months.
Of 104 industry-sponsored phase 1 interventional studies under Pain, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 9. This study's 9 months is above that.
Counting every sponsor, half of 220 studies reached it within 9 months; a quarter within 3 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Suzetrigine
Vertex Pharmaceuticals Incorporated →